RETINA CHIP TO RESTORE SIGHT LAUNCHING IN EUROPE

Science Corp's retina chip represents a breakthrough in treating age-related macular degeneration, a leading cause of vision loss in older adults. The device works by converting images into electrical signals that stimulate remaining retinal cells, allowing users to perceive light and movement. The European launch follows years of clinical research and regulatory approval. The technology targets patients who have lost central vision but retain some peripheral sight, a common pattern in age-related blindness. The startup's broader ambitions extend beyond eye implants. Science Corp is developing neural interface technology aimed at restoring motor function and treating neurological conditions through direct brain-computer interfaces. The retina chip launch establishes Science Corp as a competitor in the neural implant space alongside companies like Neuralink. Success in Europe could accelerate the company's path to U.S. regulatory approval and fund development of more complex neural applications.